KETEK from Canada (TELITHROMYCIN) is indicated for the treatment of the following infections:
In patients of 18 years and older:Community-acquired pneumonia, mild or moderate, Acute exacerbation of chronic bronchitis, Acute sinusitis, Tonsillitis/pharyngitis caused by Group A beta streptococci, as an alternative when beta lactam antibiotics are not appropriate,
In patients of 12 to 18 years old: Tonsillitis/pharyngitis caused by Group A beta streptococci, as an alternative when beta lactam antibiotics are not appropriate.
KETEK side effects may cause Hypersensitivity,Hypersensitivity to any of the macrolide antibacterial agents, or to any of the excipients. Concomitant administration of KETEK (TELITHROMYCIN) and any of the following substances is contraindicated: cisapride, ergot alkaloid derivatives (such as ergotamine and dihydroergotamine), pimozide, astemizole and terfenadine.
KETEK (TELITHROMYCIN) should not be used concomitantly with simvastatin, atorvastatin and lovastatin otherwise they may result in KETEK side effects. Treatment with these agents should be interrupted during Ketek treatment.
KETEK (TELITHROMYCIN) is contraindicated in patients with a history of congenital or a family history of long QT syndrome (if not excluded by ECG) and in patients with known acquired QT interval prolongation.
The recommended dose of KETEK (TELITHROMYCIN) is 800 mg once a day i.e. two 400 mg tablets once a day. The tablets should be swallowed whole with a sufficient amount of water. The tablets may be taken with or without food.